# **SUPPLEMENTAL MATERIAL**

**Table 1 Online Supplement:** Baseline characteristics of MonDAFIS study patients with or without Renal Impairment

(eGFR <60mL/min) on admission (n=2,947).

|  | **Renal Impairment at hospital admission (eGFR<60mL/min)** | |
| --- | --- | --- |
|  | **Yes**  n=625 | **No**  n=2,322 |
| Age, years, median [IQR] | 76 [70-81] | 65 [56-75] |
| Age categories, years (%) |  |  |
| <65 | 88 (14.1) | 1,125 (48.4) |
| 65-74 | 161 (25.8) | 612 (20.8) |
| 75-84 | 295 (47.2) | 522 (22.5) |
| >84 | 81 (13.0) | 63 (2.7) |
| Female sex (%) | 306 (49.0) | 844 (36.3) |
| Body-mass index, kg/m2 (mean (SD)) | 27.1 [24.2-30.2] | 26.7 [24.1-30.0] |
| **Index stroke** |  |  |
| TIA (%) | 169 (27.1) | 660 (28.5) |
| Stroke (%) | 454 (72.9) | 1,658 (71.5) |
| Assumed cause of stroke (%) |  |  |
| large artery atherosclerosis | 213 (34.1) | 640 (27.8) |
| cardioembolism | 93 (14.9) | 254 (11.0) |
| small artery occlusion | 152 (20.5) | 588 (25.5) |
| cryptogenic stroke | 161 (25.8) | 757 (32.8) |
| other determined etiology | 6 (1.0) | 66 (2.9) |
| NIHSS score on admission (median [IQR]) | 2 [1-4] | 2 [1-4] |
| Intravenous thrombolysis (%) | 130 (20.8) | 521 (22.5) |
| Endovascular treatment (%) | 18 (2.9) | 77 (3.3) |
| Hemicraniectomy (%) | 0 (0.0) | 4 (0.2) |
| Carotid surgery or stenting (%) | 13 (2.1) | 60 (2.6) |
| Hospital stay, days (median [IQR]) | 5 [3-8] | 5 [3-7] |
| **Cardiovascular risk factors** |  |  |
| Diabetes mellitus (%) | 227 (36.3) | 542 (23.3) |
| Hypertension (%) | 563 (90.1) | 1,716 (73.9) |
| Congestive heart failure (%) | 30 (4.8) | 57 (2.5) |
| Hypercholesterolemia (%) | 349 (55.8) | 1,232 (53.1) |
| Coronary heart disease | 138 (22.1) | 239 (10.3) |
| Peripheral arterial disease (%) | 5 (0.8) | 11 (0.5) |
| Prior ischemic stroke (%) | 135 (21.6) | 289 (12.4) |
| Prior TIA (%) | 36 (5.8) | 91 (3.9) |
| Sleep apnea (%) | 18 (2.9) | 67 (2.9) |
| Smoker (%) | 240 (38.6) | 1217 (52.8) |
| **Medication on admission** |  |  |
| Oral anticoagulationa (%) | 4 (0.6) | 5 (0.2) |
| Heparin, therapeutic dose | 10 (1.6) | 12 (0.5) |
| Antiplatelet drug (%) | 326 (52.2) | 688 (29.6) |
|  |  |  |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table 2 Online Supplement.** Adjusted survival analyses, Cox regression, results for the composite endpoint (recurrent stroke, myocardial infarction, major bleeding, all-cause death) as well as all-cause death within 24 months of the MonDAFIS study in patients with impaired kidney function at baseline (eGFR < 60ml/min/1.73m²) (n=2,947) - analyzed within those patients with baseline and follow-up eGFR value (n=1,623) | | | | | | |
| **Model** |  |  | **Composite Endpoint** | | **All-cause death** | |
|  | **eGFR (ml/min/1.73m²)** | **N** | **HR (95%CI)** | **P** | **HR (95%CI)** | **P** |
| **Crude** | ≥ 60 | 1,204 | 1 |  | 1 |  |
|  | < 60 | 419 | 1.84 (1.44-2.37) | <0.001 | 2.27 (1.56-3.31) | <0.001 |
|  |  |  |  |  |  |  |
| **Adjusted 1†** | ≥ 60 | 1,204 | 1 |  | 1 |  |
|  | < 60 | 419 | 1.41 (1.07-1.85) | 0.015 | 1.33 (0.88-1.99) | 0.179 |
|  |  |  |  |  |  |  |
| **Adjusted 2 ‡** | ≥ 60 | 1,204 | 1 |  | 1 |  |
|  | < 60 | 419 | 1.36 (1.06-1.84) | 0.019 | 1.29 (0.85-1.95) | 0.231 |

†Adjusted (1) for age, stroke severity on admission (NIHSS score), diabetes mellitus, arterial hypertension, coronary heart disease, detection of atrial fibrillation in-hospital, and randomization. ‡ Adjusted (2) for all variables of Model Adjusted 1 and for medication at discharge (anticoagulation, antiplatelet) and stroke type (ischemic stroke, TIA).

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table 3 Online Supplement.** Adjusted survival analyses, Cox regression, results for the composite endpoint (recurrent stroke, myocardial infarction, major bleeding, all-cause death) as well as all-cause death within 24 months of the MonDAFIS study according to level of estimated glomerular filtration rate (eGFR) on admission (n=2,947) | | | | | | |
| **Model** |  |  | **Composite Endpoint** | | **All-cause death** | |
|  | **eGFR (ml/min/1.73m²)** | **N** | **HR (95%CI)** | **P** | **HR (95%CI)** | **P** |
| **Crude** | ≥ 90 | 855 | 1 |  | 1 |  |
|  | 60-89 | 1,467 | 1.10 (0.87-1.41) | 0.394 | 1.49 (0.95-2.34) | 0.078 |
|  | 30-59 | 558 | 1.71 (1.31-2.24) | <0.001 | 3.05 (1.91-4.89) | <0.001 |
|  | < 30 | 67 | 3.87 (2.52-5.96) | <0.001 | 9.15 (4.91-17.1) | <0.001 |
|  |  |  |  |  |  |  |
| **Adjusted 1†** | ≥ 90 | 855 | 1 |  | 1 |  |
|  | 60-89 | 1,467 | 0.82 (0.63-1.07) | 0.151 | 1.33 (0.88-1.99) | 0.179 |
|  | 30-59 | 558 | 1.04 (0.76-1.44) | 0.795 | 1.06 (0.60-1.86) | 0.841 |
|  | < 30 | 67 | 2.22 (1.40-3.54) | 0.001 | 3.02 (1.51-6.10) | 0.002 |
|  |  |  |  |  |  |  |
| **Adjusted 2 ‡** | ≥ 90 | 855 | 1 |  | 1 |  |
|  | 60-89 | 1,467 | 0.84 (0.64-1.09) | 0.186 | 0.74 (0.45-1.23) | 0.743 |
|  | 30-59 | 558 | 1.05 (0.76-1.44) | 0.773 | 1.06 (0.61-1.86) | 0.835 |
|  | < 30 | 67 | 2.29 (1.43-3.65) | 0.001 | 3.18 (1.58-6.39) | 0.001 |

†Adjusted (1) for age, stroke severity on admission (NIHSS score), diabetes mellitus, arterial hypertension, coronary heart disease, detection of atrial fibrillation in-hospital, randomization. ‡ Adjusted (2) for all variables of Model Adjusted 1 and for medication at discharge (anticoagulation, antiplatelet) and stroke type (ischemic stroke or TIA).

**Table 4 Online Supplement.** Baseline characteristics of MonDAFIS patients with baseline and follow-up measurement of serum creatinine

levels during in-hospital stay according to dynamics (of at least 15%) of estimated glomerular filtration rate (eGFR) (n=1,623).

|  | **Dynamics of kidney function during in-hospital stay** | | | |
| --- | --- | --- | --- | --- |
|  | **stable decreased**  n=317 | **increasing**  n=231 | **decreasing**  n=74 | **stable normal**  n=1,001 |
| Age, years, median [IQR] | 77 [72-81] | 70 [61-76] | 69 [60-78] | 65 [56-75] |
| Age categories, years (%) |  |  |  |  |
| <65 | 37 (11.7) | 86 (37.2) | 29 (39.2) | 477 (47.7) |
| 65-74 | 107 (25.5) | 34 (26.4) | 17 (23.0) | 268 (26.8) |
| 75-84 | 201 (48.0) | 26 (20.2) | 25 (33.8) | 224 (22.4) |
| >84 | 56 (13.4) | 1 (0.8) | 3 (4.1) | 32 (3.2) |
| Female sex (%) | 147 (46.4) | 105 (45.5) | 33 (44.6) | 360 (36.0) |
| Body-mass index, kg/m2 (mean (SD)) | 27 [24-31] | 27 [25-31] | 28 [26-30] | 27 [24-30] |
| **Index stroke** |  |  |  |  |
| TIA (%) | 78 (24.7) | 61 (26.6) | 11 (15.1) | 250 (25.0) |
| Stroke (%) | 238 (75.3) | 168 (73.4) | 62 (84.9) | 750 (75.0) |
| **Assumed cause of stroke** (%) |  |  |  |  |
| Large artery atherosclerosis | 109 (34.4) | 70 (30.3) | 20 (27.4) | 289 (29.0) |
| Cardioembolism | 48 (15.1) | 35 (15.2) | 16 (21.9) | 113 (11.3) |
| Small artery occlusion | 77 (24.3) | 61 (26.4) | 16 (21.9) | 276 (27.7) |
| Cryptogenic stroke | 82 (25.9) | 62 (26.8) | 16 (21.9) | 300 (30.1) |
| Other determined etiology | 1 (0.3) | 3 (1.3) | 5 (6.8) | 18 (1.8) |
| NIHSS score on admission (median [IQR]) | 3 [1-5] | 3 [1-5] | 3 [1-6] | 3 [1-5] |
| **Cardiovascular risk factors** |  |  |  |  |
| Diabetes mellitus (%) | 125 (39.4) | 61 (26.4) | 16 (21.9) | 237 (23.7) |
| Hypertension (%) | 293 (92.4) | 188 (81.4) | 60 (82.2) | 748 (74.9) |
| Congestive heart failure (%) | 20 (4.8) | 0 (0.0) | 4 (5.6) | 17 (1.7) |
| Hypercholesterolemia (%) | 164 (51.7) | 109 (47.2) | 34 (46.6) | 485 (48.6) |
| Coronary heart disease | 74 (23.3) | 36 (15.6) | 11 (15.1) | 100 (10.0) |
| Peripheral arterial disease (%) | 19 (6.0) | 8 (3.5) | 0 (0.0) | 46 (4.6) |
| Prior ischemic stroke or TIA (%) | 80 (25.2) | 43 (18.6) | 13 (17.8) | 147 (14.7) |
| Sleep apnea (%) | 11 (3.5) | 6 (2.6) | 3 (4.1) | 32 (3.2) |
| Current smoker or history of smoking (%) | 112 (35.7) | 106 (46.5) | 35 (47.9) | 557 (55.9) |
| **Medication on admission** |  |  |  |  |
| Oral anticoagulation (%) | 3 (0.9) | 1 (0.4) | 0 (0.0) | 2 (0.2) |
| Heparin, therapeutic dose | 5 (1.6) | 4 (1.7) | 0 (0.0) | 8 (0.8) |
| Antiplatelet drug (%) | 183 (57.7) | 74 (32.0) | 28 (37.8) | 292 (29.2) |
| **Randomization to the intervention group (%)** | 157 (49.5) | 113 (48.9) | 43 (58.1) | 507 (50.7) |
| **Acute stroke treatment** |  |  |  |  |
| Intravenous thrombolysis (%) | 73 (23.0) | 66 (28.6) | 14 (18.9) | 246 (24.6) |
| Endovascular treatment (%) | 12 (3.8) | 8 (3.5) | 5 (6.8) | 37 (3.7) |
| Hemicraniectomy (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.2) |
| Carotid surgery or stenting (%) | 5 (1.6) | 8 (3.5) | 3 (4.1) | 31 (3.1) |
| Hospital stay, days (median [IQR]) | 6 [3-8] | 5 [3-7] | 7 [4-10] | 5 [3-8] |
| Contrast medium for angiography† (%) | 181 (43.2) | 65 (50.4) | 28 (37.8) | 460 (46.0) |

†Coronary angiography or CT angiography or digital subtraction angiography – administration of contrast medium containing iodine

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 5 Online Supplement.** Adjusted survival analyses, Cox regression, results for the composite endpoint (recurrent stroke, myocardial infarction, major bleeding, all-cause death) and all-cause death within 24 months of the MonDAFIS trial according to dynamics of kidney function (of at least **10%**) during in-hospital stay (n=1,623). | | | | | | | |
| **Model** |  |  | **Composite Endpoint**† | |  | **All-cause death** | |
|  | **eGFR** | **N**† | **HR (95%CI)** | **P** | **N** | **HR (95%CI)** | **P** |
| **Crude** | stable normal | 831 | 1 |  | 839 | 1 |  |
|  | increasing | 356 | 1.00 (0.70-1.43) | 0.996 | 357 | 1.16 (0.67-2.02) | 0.587 |
|  | decreasing | 129 | 1.79 (1.17-2.73) | 0.007 | 130 | 2.58 (1.42-4.68) | 0.002 |
|  | stabel decreased | 293 | 2.30 (1.71-3.10) | <0.001 | 297 | 2.77 (1.76-4.34) | <0.001 |
|  |  |  |  |  |  |  |  |
| **Adjusted 1‡** | stable normal | 831 | 1 |  | 839 | 1 |  |
|  | increasing | 356 | 0.91 (0.60-1.36) | 0.633 | 357 | 0.98 (0.56-1.70) | 0.929 |
|  | decreasing | 129 | 1.79 (1.07-2.99) | 0.027 | 130 | 2.32 (1.27-4.24) | 0.006 |
|  | stabel decreased | 293 | 1.64 (1.20-2.24) | 0.002 | 297 | 1.57 (0.97-2.56) | 0.069 |
|  |  |  |  |  |  |  |  |
| **Adjusted 2**§ | stable normal | 831 | 1 |  | 839 | 1 |  |
|  | increasing | 356 | 0.94 (0.65-1.34) | 0.726 | 357 | 0.97 (0.56-1.70) | 0.919 |
|  | decreasing | 129 | 1.68 (1.10-2.58) | 0.017 | 130 | 3.15 (1.64-6.03) | 0.001 |
|  | stabel decreased | 293 | 1.72 (1.24-2.37) | 0.001 | 297 | 1.53 (0.94-2.50) | 0.087 |

†In 14 patients the composite endpoint occurred before the second serum creatinine or eGFR value as measured, data of these 14 patients were excluded from the analysis for the composite endpoint only. ‡Adjusted (1) for age, stroke severity on admission (NIHSS score), diabetes mellitus, arterial hypertension, coronary heart disease, detection of atrial fibrillation in-hospital, and randomization. §Adjusted (2) for all variables of Model Adjusted 1 and for medication at discharge (anticoagulation, antiplatelet) and stroke type (ischemic stroke, TIA).

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 6 Online Supplement.** Adjusted survival analyses, Cox regression, results for the composite endpoint (recurrent stroke, myocardial infarction, major bleeding, all-cause death) and all-cause death within 24 months after the index stroke according to dynamics of kidney function (of at least **20%**) during in-hospital stay after the index stroke (n=1,623). | | | | | | | |
| **Model** |  |  | **Composite Endpoint**† | |  | **All-cause death** | |
|  | **eGFR** | **N**† | **HR (95%CI)** | **P** | **N** | **HR (95%CI)** | **P** |
| **Crude** | stable normal | 1,065 | 1 |  | 1,075 | 1 |  |
|  | increasing | 173 | 0.94 (0.59-1.49) | 0.784 | 173 | 1.04 (0.52-2.12) | 0.906 |
|  | decreasing | 41 | 2.04 (1.07-3.87) | 0.030 | 41 | 3.79 (1.72-8.33) | 0.001 |
|  | stabel decreased | 330 | 2.05 (1.56-2.70) | <0.001 | 334 | 2.54 (1.69-3.82) | <0.001 |
|  |  |  |  |  |  |  |  |
| **Adjusted 1‡** | stable normal | 1,065 | 1 |  | 1,075 | 1 |  |
|  | increasing | 173 | 0.84 (0.53-1.36) | 0.448 | 173 | 0.86 (0.42-1.74) | 0.906 |
|  | decreasing | 41 | 1.89 (0.99-3.59) | 0.053 | 41 | 3.34 (1.51-7.37) | 0.003 |
|  | stabel decreased | 330 | 1.54 (1.13-2.08) | 0.006 | 334 | 1.45 (0.93-2.27) | 0.102 |
|  |  |  |  |  |  |  |  |
| **Adjusted 2**§ | stable normal | 1,065 | 1 |  | 1,075 | 1 |  |
|  | increasing | 173 | 0.84 (0.53-1.34) | 0.472 | 173 | 0.82 (0.40-1.68) | 0.588 |
|  | decreasing | 41 | 1.89 (0.99-3.60) | 0.053 | 41 | 3.38 (1.53-7.47) | 0.003 |
|  | stabel decreased | 330 | 1.52 (1.12-2.06) | 0.007 | 334 | 1.41 (0.90-2.21) | 0.135 |

†In 14 patients the composite endpoint occurred before the second serum creatinine or eGFR value as measured, data of these 14 patients were excluded from the analysis for the composite endpoint only. ‡Adjusted (1) for age, stroke severity on admission (NIHSS score), diabetes mellitus, arterial hypertension, coronary heart disease, detection of atrial fibrillation in-hospital, and randomization. §Adjusted (2) for all variables of Model Adjusted 1 and for medication at discharge (anticoagulation, antiplatelet) and stroke type (ischemic stroke, TIA).

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 7 Online Supplement.** Adjusted survival analyses, Cox regression, results for the combined endpoint and all-cause death within 24 months after the index stroke according to dynamics of kidney function during in-hospital stay after the index stroke (n=1,623). | | | | | | | |
| **Model** |  |  | **Composite Endpoint**† | |  | **All-cause death** | |
|  | **Kidney function** | **N**† | **HR (95%CI)** | **P** | **N** | **HR (95%CI)** | **P** |
| **Crude** | ‘high’¶ | 1,145 | 1 |  | 1,155 | 1 |  |
|  | ‘rising’†† | 137 | 1.49 (0.96-2.29) | 0.074 | 137 | 1.98 (1.06-3.71) | 0.033 |
|  | ‘falling’ §§ | 49 | 2.93 (1.72-4.99) | <0.001 | 49 | 5.30 (2.70-10.4) | <0.001 |
|  | ‘reduced’¶¶ | 278 | 2.30 (1.73-3.06) | <0.001 | 282 | 2.93 (1.92-4.48) | <0.001 |
|  |  |  |  |  |  |  |  |
| **Adjusted 1**‡ | ‘high’¶ | 1,145 | 1 |  | 1,155 | 1 |  |
|  | ‘rising’†† | 137 | 1.21 (0.77-1.89) | 0.407 | 137 | 1.29 (0.68-2.45) | 0.442 |
|  | ‘falling’ §§ | 49 | 2.24 (1.30-3.87) | 0.004 | 49 | 3.23 (1.60-6.52) | 0.001 |
|  | ‘reduced’¶¶ | 278 | 1.74 (1.27-2.40) | 0.001 | 282 | 1.67 (1.05-2.68) | 0.031 |
|  |  |  |  |  |  |  |  |
| **Adjusted 2**§ | ‘high’¶ | 1,145 | 1 |  | 1,155 | 1 |  |
|  | ‘rising’†† | 137 | 0.84 (0.53-1.34) | 0.472 | 137 | 1.25 (0.65-2.38) | 0.504 |
|  | ‘falling’ §§ | 49 | 1.89 (0.99-3.60) | 0.053 | 49 | 3.25 (1.61-6.56) | 0.001 |
|  | ‘reduced’¶¶ | 278 | 1.52 (1.12-2.06) | 0.007 | 282 | 1.63 (1.02-2.62) | 0.043 |

†In 14 patients the combined endpoint occurred before the second serum creatinine level was measured, data of these 14 were excluded from this analysis, ‡Adjusted (1) for age, stroke severity on admission (NIHSS score), diabetes mellitus, arterial hypertension, coronary heart disease, detection of atrial fibrillation in-hospital, randomization, §Adjusted (2) for all variables of Model Adjusted 1 and for medication at discharge (anticoagulation, antiplatelet) and stroke type (ischemic stroke, TIA), ¶both eGFR ≥ 60ml/min, ††eGFR basline < 60ml/min, follow-up ≥ 60ml/min, §§eGFR baseline ≥ 60ml/min, follow-up < 60ml/min, ¶¶both eGFR < 60ml/min.

**Table 8 online supplement:** Baseline characteristics of MonDAFIS patients with normal stable eGFR or increasing eGFR within the in-hospital stay (n=1,232).

|  | **Univariate** | | | **Multivariate** | |
| --- | --- | --- | --- | --- | --- |
|  | **stable eGFR**  n=1,001 | **increasing eGFR**  n=231 | ***P*** | **OR 95%CI** | ***P*** |
| Age, years, median [IQR] | 65 [56-75] | 70 [61-76] | <0.001 | 0.95 (0.93-0.97) | <0.001 |
| Age categories, years (%) |  |  | 0.028 | - | - |
| <65 | 477 (47.7) | 86 (37.2) |  | - | - |
| 65-74 | 268 (26.8) | 34 (26.4) |  | - | - |
| 75-84 | 224 (22.4) | 26 (20.2) |  | - | - |
| >84 | 32 (3.2) | 1 (0.8) |  | - | - |
| Female sex (%) | 360 (36.0) | 105 (45.5) | 0.008 | 1.03 (0.69-1.55) | 0.871 |
| Body-mass index, kg/m2 (median) | 27 [24-30] | 27 [25-31] | 0.012 | 1.01 (0.96-1.05) | 0.806 |
| eGFR on admission, ml/min/1.73m² (median, IQR) | 87 [76-96] | 62 [55-72] | <0.001 | 0.85 (0.83-0.87) | <0.001 |
| 2nd eGFR in-hospital, ml/min/1.73m² (median, IQR) | 88 [77-96] | 82 [72-91] | <0.001 | n.a. | n.a. |
| **Index stroke** |  |  | 0.614 | - | - |
| TIA (%) | 250 (25.0) | 61 (26.6) |  |  |  |
| Stroke (%) | 750 (75.0) | 168 (73.4) |  |  |  |
| **Assumed cause of stroke** (%) |  |  | 0.487 | - | - |
| Large artery atherosclerosis | 289 (29.0) | 70 (30.3) |  |  |  |
| Cardioembolism | 113 (11.3) | 35 (15.2) |  |  |  |
| Small artery occlusion | 276 (27.7) | 61 (26.4) |  |  |  |
| Cryptogenic stroke | 300 (30.1) | 62 (26.8) |  |  |  |
| Other determined etiology | 18 (1.8) | 3 (1.3) |  |  |  |
| NIHSS score on admission (median [IQR]) | 3 [1-5] | 3 [1-5] | 0.173 | - | - |
| **Cardiovascular risk factors** |  |  |  |  |  |
| Diabetes mellitus (%) | 237 (23.7) | 61 (26.4) | 0.395 | - | - |
| Hypertension (%) | 748 (74.9) | 188 (81.4) | 0.040 | 0.71 (0.42-1.21) | 0.211 |
| Congestive heart failure (%) | 17 (1.7) | 0 (0.0) | 0.554 | - | - |
| Hypercholesterolemia (%) | 485 (48.6) | 109 (47.2) | 0.715 | - | - |
| Coronary heart disease | 100 (10.0) | 36 (15.6) | 0.020 | 1.11 (0.63-1.96) | 0.727 |
| Peripheral arterial disease (%) | 46 (4.6) | 8 (3.5) | 0.593 | - | - |
| Prior ischemic stroke or TIA (%) | 147 (14.7) | 43 (18.6) | 0.157 | - | - |
| Sleep apnea (%) | 32 (3.2) | 6 (2.6) | 0.833 | - | - |
| Current smoker or history of smoking (%) | 557 (55.9) | 106 (46.5) | 0.012 | 0.819 (0.54-1.24) | 0.346 |
| **Medication on admission** |  |  |  |  |  |
| Oral anticoagulation (%) | 2 (0.2) | 1 (0.4) | 0.464 | - | - |
| Heparin, therapeutic dose | 8 (0.8) | 4 (1.7) | 0.254 | - | - |
| Antiplatelet drug (%) | 292 (29.2) | 74 (32.0) | 0.424 | - | - |
| **Randomization to the intervention group (%)** | 507 (50.7) | 113 (48.9) | 0.662 | - | - |
| **Acute stroke treatment** |  |  |  |  |  |
| Intravenous thrombolysis (%) | 246 (24.6) | 66 (28.6) | 0.209 | - | - |
| Endovascular treatment (%) | 37 (3.7) | 8 (3.5) | 1.000 | - | - |
| Hemicraniectomy (%) | 2 (0.2) | 0 (0.0) | 1.000 | - | - |
| Carotid surgery or stenting (%) | 31 (3.1) | 8 (3.5) | 0.835 | - | - |
| Hospital stay, days (median [IQR]) | 5 [3-8] | 5 [3-7] | 0.500 | - | - |
| Contrast medium for angiography (%) | 460 (46.0) | 65 (50.4) | 0.306 | - | - |

†Coronary angiography or CT angiography or digital subtraction angiography – administration of contrast medium containing iodine

**Table 9 online supplement:** Baseline characteristics of MonDAFIS patients with one or two measurements of serum creatinine level during the in-hospital stay (n=2,947).

|  | **Second measurement of serum creatinine** | |
| --- | --- | --- |
|  | No  n=1324 | Yes  N=1623 |
| Age, years, median [IQR] | 66 [58-76] | 69 [59-77] |
| Age categories, years (%) |  |  |
| <65 | 584 (44.1) | 629 (38.8) |
| 65-74 | 347 (26.2) | 426 (26.2) |
| 75-84 | 341 (25.8) | 476 (29.8) |
| >84 | 52 (3.9) | 92 (5.7) |
| Female sex (%) | 505 (38.1) | 645 (39.7) |
| Body-mass index, kg/m2 (mean (SD)) | 27 [24-30] | 27 [24-30] |
| **Index stroke** |  |  |
| TIA (%) | 429 (32.4) | 400 (24.7) |
| Stroke (%) | 894 (67.6) | 1,218 (75.3) |
| **Assumed cause of stroke** (%) |  |  |
| Large artery atherosclerosis | 365 (27.8) | 488 (30.2) |
| Cardioembolism | 135 (10.3) | 212 (13.1) |
| Small artery occlusion | 310 (23.6) | 430 (26.6) |
| Cryptogenic stroke | 458 (34.9) | 460 (28.4) |
| Other determined etiology | 45 (3.4) | 27 (1.7) |
| NIHSS score on admission (median [IQR]) | 2 [1-4] | 3 [1-5] |
| **Cardiovascular risk factors** |  |  |
| Diabetes mellitus (%) | 330 (25.0) | 439 (27.1) |
| Hypertension (%) | 990 (74.9) | 1,289 (79.6) |
| Congestive heart failure (%) | 25 (1.9) | 41 (2.6) |
| Hypercholesterolemia (%) | 789 (59.7) | 792 (48.9) |
| Coronary heart disease | 155 (11.7) | 221 (13.7) |
| Peripheral arterial disease (%) | 52 (3.9) | 73 (4.5) |
| Prior ischemic stroke or TIA (%) | 233 (17.6) | 283 (17.5) |
| Sleep apnea (%) | 33 (2.5) | 52 (3.2) |
| Current smoker or history of smoking (%) | 647 (49.2) | 810 (50.3) |
| **Medication on admission** |  |  |
| Oral anticoagulation (%) | 3 (0.2) | 3 (0.4) |
| Heparin, therapeutic dose | 5 (0.4) | 17 (1.0) |
| Antiplatelet drug (%) | 437 (33.0) | 577 (35.6) |
| **Randomization to the intervention group (%)** | 671 (50.7) | 820 (50.5) |
| **Acute stroke treatment** |  |  |
| Intravenous thrombolysis (%) | 252 (19.0) | 399 (24.6) |
| Endovascular treatment (%) | 33 (2.5) | 62 (3.8) |
| Hemicraniectomy (%) | 2 (0.2) | 2 (0.1) |
| Carotid surgery or stenting (%) | 26 (2.0) | 47 (2.9) |
| Hospital stay, days (median [IQR]) | 4 [2-6] | 5 [3-8] |
| Contrast medium for angiography (%) | 510 (38.5) | 734 (45.2) |

†Coronary angiography or CT angiography or digital subtraction angiography – administration of contrast medium containing iodine

# 

# **Figure 1 Online Supplement.** Derivation of the study population.

MonDAFIS complete randomized set

n=3,431

Available creatinine or eGFR level

on hospital admission

n=2,947

Normal or increased glomerular filtration rate (eGFR ≥ 90mL/min)

n=855 (29.0%)

Mildly reduced glomerular filtration rate (eGFR 60-89mL/min)

n=1,467 (49.8%)

Moderately reduced glomerular filtration rate (eGFR 30-59mL/min)

n=558 (18.9%)

Severely reduced glomerular filtration rate (eGFR 15-29mL/min)

n=56 (1.9%)

Kidney failure (eGFR < 15mL/min), n=11 (0.4%)

“stable normal” eGFR (≥ 60mL/min)”

n=1,001 (61.7%)

Available follow-up creatinine or

eGFR level

during in-hospital stay

n=1,623

“increasing”\* eGFR

n=231 (14.2%)

“decreasing”† eGFR

n=74 (4.6%)

“stable decreased” (< 60ml/min)

n=317 (19.5%)

\*of at least 15% - including patients with a baseline eGFR of < 60ml/min and the second value of ≥ 60ml/min reached by an increase of at least 15%, †of at least 15% in patients with a baseline eGFR ≥ 60ml/min